News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
New Ovarian Cancer Vaccine Shows Promise
Catherine Offord | Apr 12, 2018
A preliminary clinical trial finds that the personalized therapy improves survival rates and has no severe side-effects.
Stem Cell Vaccine Protects Mice From Cancer
Ruth Williams | Feb 15, 2018
Stem cells and cancer cells have enough molecular similarities that the former can be used to trigger immunity against the latter.
Locally-Injected Immunotherapy Eradicates Tumors in Mice
Diana Kwon | Feb 1, 2018
The treatment also curbed the growth of nearby metastases that did not receive the drug.
Personalized Cancer Vaccines Show Promise for Melanoma
Jef Akst | Jul 6, 2017
In two early trials, vaccines tailored to the mutations in individuals’ cancers appeared to protect 12 of 19 patients against relapse.
Researchers Call for Retraction of Paper that Questions HPV Vaccine
Jef Akst | Dec 23, 2016
Oncologists have raised concerns about a mouse study that suggests the vaccine for human papillomavirus could cause brain damage.
Viral Immunotherapy for Melanoma
Kerry Grens | May 28, 2015
Phase 3 data from a clinical trial show a positive response to a melanoma treatment based on a modified herpesvirus.
Personalized Cancer Vaccines
Anna Azvolinsky | Apr 2, 2015
A dendritic cell vaccine targeting melanoma patients’ tumor-specific mutations can activate a broad range of cancer-fighting T cells.
Opinion: Making Cancer Vaccines Work
Abhishek Srivastava and Haval Shirwan | Mar 31, 2015
Armed with the right adjuvant system, vaccines are poised to tackle one of the world’s most intractable diseases.
Week in Review: June 23–27
Tracy Vence | Jun 27, 2014
Tracking chikungunya virus; reconsidering wood decay-based fungal classification; ASC specks spread inflammation; antibiotic tolerance in
; RIKEN review yields corrections
Targeted Brain Cancer Vaccine
Anna Azvolinsky | Jun 25, 2014
Mouse study demonstrates the ability of a cancer vaccine targeted against a specific oncogenic mutation to elicit a protective anti-tumor immune response.